stockrow
Friday 6 November 2026
Export NNNN’s income statement to Excel — free account
Anbio Biotechnology
NNNN Healthcare Medical Instruments & Supplies
Anbio Biotechnology’s revenue for fiscal 2025 (year ended December 2025) was $8.6 million, up 5.64% from fiscal 2024.
3.92
0.33
+9.19%
Follow NNNN
Alert me
Anbio Biotechnology (NNNN) P/E ratio
P/E ratio, daily
Annual newest first
| Period | P/E ratio | Change |
|---|
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SMTI Sanara MedTech Inc. compare | n/m |
| OSUR OraSure Technologies, Inc. compare | n/m |
| ANGO AngioDynamics, Inc. compare | n/m |
| EMBC Embecta Corp. compare | 4.2× |
| PDEX Pro-Dex, Inc. compare | 16.8× |
| UTMD Utah Medical Products, Inc. compare | 22.0× |
| STAA STAAR Surgical Company compare | 84,233× |
| NNNN Anbio Biotechnology | — |
| ZJYL Jin Medical International Ltd. compare | — |
| Medical Instruments & Supplies industry median | 30.8× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)